Contact Us
  • Choose License Type

Global Subcutaneous Drug Delivery Market, by Usability (Disposable and Reusable), by Disease Indication (Auto-immune Disorders, Neurological Disorders, Oncology Disorders, Hormonal Disorders, Allergy and Infectious Disorders, Ophthalmic Disorders, and Others), by Delivery Type (Prefilled Syringe, Autoinjector (Spring Type, Motorized Type, and Wearable Type), Prefilled Pen (Disposable and Reusable), Vial (Syringe), and Pump and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 9,111.6 million in 2020 and is expected to exhibit a CAGR of 9.7% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Prefilled syringes are ready-to-use disposable syringes that contain premeasured dosage. It reduces dosing errors and increases patient compliance, dosing accuracy, convenience, and safety. Combination products, particularly injectable drug delivery systems such as prefilled syringes are largely being adopted, with increasing number of injectable biological drugs, by healthcare professionals, owing to higher convenience.

According to the study named Growth & Benefits of Pre-Filled Syringes by Fisher Clinical Service, 2014, around 13 biotechnology products were available commercially in the market in 1989, which increased to 210 in 2012. As per Fisher Clinical Service, in 2013, the prefilled syringes segment was expected to account for a quarter of the total injectable drug delivery systems, which included around 35 of the 100 top-selling drugs, which were to be incorporated in the form of injection.

In April 2020, Teva Pharmaceuticals USA, Inc. launched the autoinjector device for AJOVY (fremanezumab-vfrm) injection in the U.S. market. AJOVY is indicated for the preventive treatment of migraine in adults and is given subcutaneously to the patients. Also, in December 2016, Becton, Dickinson and Company announced the launch of BD Neopak 2.25 mL prefillable glass syringe, which is developed for biopharmaceutical manufacturers focused on manufacturing of sensitive biologic drugs for the treatment of chronic diseases such as rheumatoid arthritis, psoriasis, lupus, and severe asthma. The syringe offers higher volume subcutaneous injections, thereby helping to improve safety and convenience for patients.

Global Subcutaneous Drug Delivery Market – Impact of Coronavirus (Covid-19) Pandemic

  • The COVID-19 pandemic has drastically affected clinical trials. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they have stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.
  • Moreover, the U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on June 03, 2020.
  • However, research institutes are conducting clinical trials for the treatment of COVID-19 by administering potential drugs subcutaneously
  • For instance, University Hospital of La Princesa initiated phase 2 clinical trial on April 13, 2020, to determine the safety and efficacy of Sarilumab administered subcutaneously for the treatment of COVID-19. The study is expected to be completed in June 2020.
  • Furthermore, ongoing clinical trials are being conducted by healthcare facilities and researchers using the following safety measures:
    • The healthcare providers are obtaining consent from patients over the phone or through video conferences. According to a survey conducted by Medidata Solutions, Inc., on April 23, 2020, 45% respondents opted for virtual/telemedicine for consultancy.
    • The patients receive a phone call for the screening of COVID-19 symptoms before they schedule in-person visits
    • The assessment of the studies are being done in single outpatient areas

Browse 45 Market Data Tables and 47 Figures spread through 282 Pages and in-depth TOC on “Global Subcutaneous Drug Delivery Market, by Usability (Disposable and Reusable), by Disease Indication (Auto-immune Disorders, Neurological Disorders, Oncology Disorders, Hormonal Disorders, Allergy and Infectious Disorders, Ophthalmic Disorders, and Others), by Delivery Type (Prefilled Syringe, Autoinjector (Spring Type, Motorized Type, and Wearable Type), Prefilled Pen (Disposable, and Reusable), Vial (Syringe), and Pump and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global subcutaneous drug delivery market, click the link below:

https://www.coherentmarketinsights.com/market-insight/subcutaneous-drug-delivery-market-2933

Key players operating in the market are focused on adopting various inorganic growth strategies such as collaborations, partnerships, and agreements, in order to expand their product offerings in the market. For instance, in May 2019, Insulet Corporation announced partnership with distributor, Theras Group and Nordic Infucare, to enhance distribution of its Omnipod System in Italy, Sweden, Norway, Denmark, Finland, and other European countries.

Furthermore, small companies are focused on the development of novel epinephrine auto injectors, which offer thermal stability. Currently available products work optimally at specific temperatures, thereby providing growth opportunity for manufacturers in the global subcutaneous drug delivery market. For instance, Windgap Medical is focused on developing a portable device that would mix a dry formulation of the drug into solution, thus providing temperature stability and a longer shelf-life of medication, for patients suffering from anaphylaxis due to an acute allergy attack.

Key Takeaways of the Global Subcutaneous Drug Delivery Market:

  • The global subcutaneous drug delivery market is expected to exhibit a CAGR of 9.7% over the forecast period, owing to increased product launches and approvals. For instance, in January 2019, Becton, Dickinson and Company received the U.S. Food and Drug Administration (FDA) approval for second generation BD Nano pen needle, designed for more reliable subcutaneous injection in diabetic patients.
  • Among usability, disposable segment is expected to hold a higher market share in 2020, owing to significant increase in self-administration of drugs to treat chronic diseases
  • Among disease indication, auto-immune disorders segment held a higher market share in 2018, owing to rising prevalence of autoimmune diseases such as multiple sclerosis and new approvals for injector devices
  • Companies operating in the global subcutaneous drug delivery market include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc., Novartis International AG, Insulet Corporation, West Pharmaceutical Services, Inc., and Gerresheimer AG
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner